Oncology
Categories
Early Phase / Multiple Disease Site 25
Precision Medicine 1
Preventative, Supportive Care, and Wellness 1
Brain and Spine Cancers 5
Breast 7
Cell Therapy Protocols 8
Endocrine Cancers
Eye/Orbital Cancers
GI Cancers 14
Gynecologic Cancers 16
Prostate and Urologic Cancers 22
Head and Neck 11
Hematologic / Blood Related Cancers 38
Sarcoma 7
Skin 6
Thoracic and Chest Cancers 17
Protocols
ALLIANCE-A041501-ALL Phase III OPEN TO ACCRUAL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
ALLIANCE-A041703 Phase II OPEN TO ACCRUAL
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Phnegative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults With Relapsed or Refractory Disease and Feasibility Study of Ponatinib With Inotuzumab Ozogamicin Followed By Ponatinib With Blinatumomab for Ph-Positive CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults
ALLIANCE-MM1MDS-A01 Phase II OPEN TO ACCRUAL
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study
ASCENTAGE-APG2575MG301-GLORA-4 Phase III OPEN TO ACCRUAL
A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)
AZ-D7405C00001-B-ALL Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
BEIGENE-BGB-11417-103 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
BEIGENE-BGB-16673-104 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination with Other Agents in Patients with Relapsed or Refractory B-Cell Malignancies
BEONE-BG-75098-101 Phase I OPEN TO ACCRUAL
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
BEONE-BGB-11417-304 Phase III OPEN TO ACCRUAL
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patient With Previously Untreated Chronic Lymphocytic Leukemia
CCTG-MM1YA-CTG01 Phase II OPEN TO ACCRUAL
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
CTN-2203 Phase III OPEN TO ACCRUAL
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
DAIICHI-SANKYO-DS3201-343 Phase I OPEN TO ACCRUAL
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
DAIICHI-SANKYO-DS3939-077 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
DISC-0974-102 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
ECOG-EA4232 Phase III OPEN TO ACCRUAL
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
ECOG-EA7222 Phase III OPEN TO ACCRUAL
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
ECOG-MM1OA-EA02 Phase II OPEN TO ACCRUAL
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
HJKC3-0003 Phase II OPEN TO ACCRUAL
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
IIT-AKHTAR-CILTA-TALQ Phase I OPEN TO ACCRUAL
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
INCYTE-INCA035784-101 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
INNOCARE-ICP-CL-01205 Phase I OPEN TO ACCRUAL
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
KURA-KO-MEN-007 Phase I OPEN TO ACCRUAL
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
KURA-KO-MEN-008 Phase I OPEN TO ACCRUAL
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia
KURA-KO-MEN-015 Phase I OPEN TO ACCRUAL
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
KURA-KO-MEN-017 Phase III OPEN TO ACCRUAL
Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
MERCK-MK2140-011-00 Phase II OPEN TO ACCRUAL
A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-Naïve Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
MODERNA-MRNA-2808-P101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
NOVARTIS-CABL001A2001B Phase IV OPEN TO ACCRUAL *
An Open-Label, Multi-Center Asciminib Roll-Over Study to Assess Long-Term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
NRG-HN006 Phase II/III OPEN TO ACCRUAL
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
NRG-HN010 Phase II OPEN TO ACCRUAL *
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
STEMLINE-MEN2312-01 Phase I OPEN TO ACCRUAL
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
SWOG-MM1OA-S03 Phase II OPEN TO ACCRUAL
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
SWOG-MM1YA-S01 Phase II OPEN TO ACCRUAL
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
TERREMOTO-TER-2013-C01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
TEVA-TV56278-ONC-10203 Phase I OPEN TO ACCRUAL
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors
UCHICAGO-IRB23-1681 Phase I OPEN TO ACCRUAL
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs